AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06337773 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-weeks's on-line precision nursing education program
Description: The intervention involved 8-weeks's on-line precision nursing education program, including Qigong exercise, and mindfulness training.
Study NCT06308796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of CaP dental mousse
Description: Application of calcium phosphate (CaP) mousse on dental surfaces at home, once a day for 3 months; followed, as maintenance, once a day for just one week a month.
Study NCT05946837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) dye
Description: ICG (25 mg vial) will be reconstituted with 10 ml sterile water provided by the manufacturer; further dilutions will be made in sterile saline just prior to administration. The final concentration of 0.32 millimolar (mM) will provide 25 μg ICG/injection, with each injection of 0.1 cc to be made . Up to 30 intradermal injections using conventional 30- or 31-gauge needles will be administered to each subject, for a maximum dose of 750 ug ICG, over 200 times less than the maximum allowed dose. Injection sites will be cleaned with alcohol wipes before intradermal injection.
Study NCT05946837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRF-LI imaging
Description: Near-infrared fluorescence lymphatic imaging (NIRF-LI) imaging will be done to assess the drainage of ICG laden lymph from ICG injection sites toward regional nodal basins for 60 minutes before, during and after the Neuroglide pad treatment
Study NCT05946837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroglide pad
Description: After injection of Indocyanine green (ICG) dye and NIRF-LI imaging the subject will lie on the Neuroglide pad for the one-hour PCT treatment session.
Study NCT06157970 — intervention group
Intervention type: PROCEDURE
Intervention: Sphenopalatine Ganglion Block
Description: For SPGB, the plastic part of the 16G angiogram is advanced transnasally into both nostrils, with the patient in the supine position and the head in 15-20° extension, until it contacts the posterior mucosa, and after contact, it is withdrawn 1 mm and 2 ml of 0.5% bupivacaine is dripped into the postnasal space within 1 minute. is applied.
Study NCT04835974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 1- LDL-C (low-density lipoprotein cholesterol)| and HDL-C(high-density lipoprotein cholesterol) Ratio. 2- Glycemia will be assessed : RBS ( random blood sugar ) . 3- S
Description: Blood samples were obtained before PCI, and the following parameters will be measured:~1. LDL-C (low-density lipoprotein cholesterol)\| and HDL-C(high-density lipoprotein cholesterol) Ratio.~2. Glycemia will be assessed : RBS ( random blood sugar ) .~3. Serum Uric acid : S .UA
Study NCT05309811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL therapy
Description: Each RLRL treatment lasts three minutes. RLRL treatments will be performed twice a day, with at least four hours between each RLRL treatment.
Study NCT05309811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine IOP-lowering medications
Description: Medications prescribed for IOP control by glaucoma specialists in the outpatient.
Study NCT04650217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa/levodopa
Description: L-DOPA is the immediate precursor of dopamine, is converted to dopamine in presynaptic dopaminergic nerve terminals, and enhances dopaminergic transmission in multiple brain regions. Subjects assigned to L-DOPA will begin with a Week 1 L-DOPA daily dosage of 150mg, or 1.5 25mg carbidopa/100mg levodopa tablets at 9am and placebo tablets at~1pm and 5pm. In Week 2 the L-DOPA daily dose will increase to 300mg (1.5 25mg carbidopa/100mg levodopa tablets at 9am and 5pm, with placebo at 1pm), followed by a Week 3 to 8 L-DOPA daily dose of 450mg (1.5 25mg carbidopa/100mg levodopa tablets three times daily). Subjects assigned to placebo will take 1.5 placebo tablets three times daily for three weeks. Individuals will be instructed to maintain the same timing of doses throughout the study. Individuals unable to tolerate an increased dose will have their dosage reduced to the maximum previously tolerated dose.
Study NCT04650217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Carbidopa/levodopa matched placebo
Study NCT04650217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
Study NCT04650217 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise training
Description: Subjects assigned t Exercise will exercise individually at their home on a program set each week by Dr. Sloan and the research assistant (RA) coach, who will work with the patient to ensure they train according to the program at the appropriate level of intensity. Subjects will select from a series of aerobic activities and for Weeks 1-2 will train at 55-65 percent of maximum HR as established during their qualifying CPET. In Weeks 3-4, they will increase exercise intensity to 65-75 percent of maximum HR, and in Weeks 5-12 they will train at 75 percent of maximum HR.
Study NCT04650217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
Study NCT04650217 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control will engage in a series of stretches and toning exercises designed to promote flexibility and improve core strength.
Study NCT05571982 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume breathing technique
Description: High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Tidal volume breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
Study NCT05571982 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vital capacity breathing technique
Description: High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system before anesthetic induction. Vital capacity breathing will be applied. Pulse oximetry, end-tidal O2, and oxygen reserve index will be monitored continuously.
Study NCT05308901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV every 3 weeks for a maximum of 2 years.
Study NCT05308901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg daily for a maximum of 2 years.
Study NCT06107335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin (colloid)
Description: Fluid replacement will be achieved with colloid (5% albumin infusion). A bolus infusion of up to 500 milliliters (mL) of 5% Albumin will be administered prior to the placement of neuraxial anesthesia. If stroke volume variation (SVV) drops to less than 13% during the infusion of albumin, the infusion will be halted. At the completion of the placement of the spinal/combined spinal-epidural (CSE) anesthesia, study participants will receive the remaining albumin infusion if it was initially halted and SVV increases back to >13% during the procedure (to a total maximum of 500 mL albumin for the entire procedure).
Study NCT06107335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's Injection (crystalloid)
Description: Fluid restriction will be achieved with crystalloid (lactated ringer's injection) administered at a keep-the-vein-open (KVO) rate of 75 milliliters per hour (mL/hr), administered during the procedure.
Study NCT06107335 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards HemoSphere monitor with ClearSight-Acumen finger cuff
Description: Use of colloid will be guided by stroke volume variation (SVV) as assessed by the Edwards HemoSphere monitor with ClearSight-Acumen finger cuff device. The Edwards HemoSphere monitor with ClearSight-Acumen (CSA) finger cuff is a hemodynamic monitoring system that obtains continuous blood pressure readings from a cuff on the finger. In study participants, the finger cuff will be placed on the middle finger of one of the hands. The Edwards device can be used to predict impending intraoperative hypotension before its occurrence. The device has the ability to assess vasodilatory status using systemic vascular resistance (SVR), volume status using stroke volume variation (SVV) and stroke volume (SV) and the use of Carbon Monoxide (CO) to assess for underlying cardiac suppression. It also incorporates the hypotension prediction index (HPI), an algorithm that uses the arterial waveform to predict early phases of intraoperative hypotension.
Study NCT05600842 — intervention group
Intervention type: RADIATION
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: IMRT will be given in 30 daily fractions at 2 Gy per fraction (60 Gy total) beginning Day 1; Six fractions will be delivered per week. High risk patients will receive induction chemotherapy with 2 cycles of carboplatin and paclitaxel.
Study NCT04051346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
Study NCT04051346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oxalate Diet
Description: Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
Study NCT04764695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: D2O dilution technique
Description: Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.
Study NCT05584917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tegner acticity scale
Description: phone call to complete the tegner activity scale after surgery
Study NCT05654740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Experiences
Description: Virtual Reality experiences including stress reduction, distraction and entertainment
Study NCT06271395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable Type A Botulinum Toxin
Description: Injectable Type A Botulinum Toxin (National Medical Products Administration Approval Number S10970037) 100 unit, diluted with 1ml of 0.9% sodium chloride solution for injection and kept ready for use. Only once. Using an ultrasound probe to scan the neck, the position of the lowest point, highest point, and lower middle point of the esophageal high-pressure zone are determined, and marks are made on the body surface and catheter wall. The high-pressure point and the lower middle point are selected as injection sites on the left side. The above area is locally disinfected, and the probe is covered with a sterile cover and coated with sterile coupling agent. Using a plane approach, 0.3ml or 30 unit of botulinum toxin is injected separately after reaching the esophageal circular layer at each of the two left injection points. A total of 60 unit of botulinum toxin is injected at the two left points.
Study NCT05550935 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High-flow Nasal Cannula
Description: HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
Study NCT05550935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow Nasal Cannula
Description: HFNC is a device that, in this study, will give the maximum flow (60 L/min), with minimum adjusted temperature (31°C) and FiO2 of 21% or room air.
Study NCT05739461 — intervention group
Intervention type: OTHER
Intervention: Dental implant
Description: Dental implants with triangular cross-section neck design
Study NCT04681963 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment within 4 hours of admission
Description: Demographics, Symptoms, Severity scores (Triage at admission, confusion, urea, respiration, blood pressure, age (CURB 65) and pneumonia severity score (PSI), clinical parameters, blood testing, chest x-rays, comorbidities, electro-cardiogram
Study NCT05868837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000 mg IV on RCP days 1 and 15
Study NCT05868837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1000 mg IV on RCP days 1 and 15
Study NCT04610398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: s. arm/group description
Study NCT04610398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: s. arm/group description
Study NCT05611554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Psychological intervention focused on (a) values clarification, (b) defusion strategies, (c) training in flexible attention to the present moment (mindfulness), and (d) committed action and psychological acceptance through metaphors and experiential exercises.
Study NCT05832632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Basics Program
Description: 30-day smartphone-based mindfulness intervention consisting of 10 minutes per day. The program consist of generic mindfulness techniques such as breath awareness, body scans, mindful noting of thoughts and emotions.
Study NCT05832632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Breathing Exercises
Description: 30-day smartphone-based breathing exercises. Each exercise consists of box breathing for 1 minute and participants are instructed to complete 10 sessions corresponding to 10 minutes per day.
Study NCT05832632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Headspace Stress Program
Description: 20-day smartphone-based mindfulness intervention consisting of 15 minutes per day. The Stress program content is based on well-established concepts and practices within stress management, and mindfulness, and is targeted to people with elevated stress.
Study NCT05832632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (Audiobook)
Description: 30-day smartphone-based Audiobook book consisting of 10 minutes per day.
Study NCT05572164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRADITIONAL EPIDURAL
Description: epidural technique used for intraoperative analgesia (the EPL group; local anesthetics will be delivered via epidural catheter guided by SPI to provide intraoperative analgesia)
Study NCT05572164 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DURAL PUNCTURE EPIDURAL
Description: group on whom dural puncture epidural technique used for intraoperative analgesia ( the DPL group; local anesthetics will be delivered via an epidural catheter placed after a dural pucture performed with the SPI guidance to provide intraoperative analgesia)
Study NCT05501834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supracondylar Pin Removal Before Imaging
Description: Patients in the treatment group will: 1. Go to cast room for cast removal, 2. Have pins immediately pulled after cast removal, 3. Go to radiology for X-ray, 4. Will be seen in clinic room by provider. The order of these steps differs from our current standard of care, during which patients' pins are removed following cast removal and x-ray imaging.
Study NCT05243082 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Radio frequency ablation
Description: Radio frequency ablation of pancreatic neuroendocrine tumors
Study NCT05711823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant in combination with granisetron and dexamethasone
Description: Patients with unresectable hepatocellular carcinoma will receive aprepitant in combination with granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
Study NCT05711823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron and dexamethasone
Description: Patients with unresectable hepatocellular carcinoma will receive granisetron and dexamethasone during the therapeutic process of hepatic arterial infusion chemotherapy.
Study NCT05004220 — intervention group
Intervention type: PROCEDURE
Intervention: Plasmapheresis
Description: Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor.
Study NCT00657579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, low concentration
Study NCT00657579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, medium concentration
Study NCT00657579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-104 ophthalmic solution, high concentration
Study NCT00657579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-104 vehicle
Study NCT06507696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice Application
Description: Drinking water was placed in a syringe and filled in the refrigerator
Study NCT06507696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wetted Gauze Application
Description: Sterile gauze soaked with drinking water
Study NCT06307093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPH-075
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)
Study NCT06307093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda®
Description: 100 mg/4 mL (25 mg/mL) concentrate for solution for infusions in a single-dose vial~The required volume (8 ml) of the Drug concentrate solution should be withdrawn from the vials and transferred into an intravenous bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection. (The final concentration of the diluted solution should be between 1 mg/mL to 10 mg/mL.)
Study NCT06153368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+mFOLFIRINOX
Description: Cadonilimab 6 mg/kg，IVD，D1，Q2W~+mFOLFIRINOX（Oxaliplatin 85 mg/m2 IV over 4 hours ; Irinotecan 150 mg/m2 IV over 90 minutes ; Leucovorin(l-LV) 400 mg/m2 IV over 2 hours 5-fluorouracil 2.4 g/m2 for 46 hours continuous infusion.） on days 2 of a 14-day cycle.
Study NCT05792189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timed Up and Go Test on subjects with ORIF of distal femur fractures
Description: Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
Study NCT05792189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Koos Jr assesment on subjects with ORIF of distal femur fractures
Description: Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.
Study NCT05792189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timed Up and Go Test on subjects with DFR of distal femur fracture
Description: Subjects will perform the Timed Up and Go Test This test is used to assess mobility. Subjects are asked to wear regular footwear and can use their walking device as needed. Subjects begin by sitting in a standard armchair. Next participants are instructed to walk 10 feet to a designated line at a normal pace. Once they reach the line they are to turn and walk back to the chair and sit down. The test starts on the study staff go signal and ends once the subject is fully seated in the chair. Test will be performed at 6 weeks, 3 months, 6 months, 12 months and 24 months post surgical treatment.
Study NCT05792189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Koos Jr assesment on subjects with DFR of distal femur fracture
Description: Subjects will complete the KOOS Jr assessment. The Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. The maximum score a patient can achieve is 100, indicating no knee problems. The minimum score is zero, indicating severe knee problems.